Alnylam Launches Phase II Trial of Second-Generation Amyloidosis Drug | GenomeWeb

Alnylam Pharmaceuticals announced this week that it has begun a phase II trial of its TTR-mediated amyloidosis drug ALN-TTR02 to test the compound's clinical activity, safety, and tolerability.

In the study, approximately 20 ATTR patients will receive increasing doses of the drug once every four weeks for two cycles, the company said. “The primary objectives of the study are to evaluate the safety and tolerability of multiple doses of ALN-TTR02 and to measure clinical activity based on serial measurement of circulating serum TTR levels.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.